Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
TER Benefits From Robust Semiconductor Test Segment: What's Ahead?

TER Benefits From Robust Semiconductor Test Segment: What's Ahead?

FinvizFinviz2026/02/19 17:12
By:Finviz

Teradyne TER is experiencing strong growth in its semiconductor test segment. In the fourth quarter of 2025, Semiconductor Test revenues were $883 million, accounting for approximately 81.5% of total sales. This reflects 45% year-over-year growth and a 46% sequential increase compared with the third quarter of 2025. This growth was fueled by increasing demand for AI-driven compute and memory applications, which have become a significant portion of Teradyne's business.

The semiconductor test segment, particularly the System-on-Chip (SoC) and memory test divisions, has shown impressive year-over-year growth. In 2025, SoC test revenue grew 23% year over year, driven by networking and VIP compute, while memory test revenue saw slight growth in a flat market, supported by share gains in high-bandwidth memory and DRAM final tests.  

Compute has emerged as the largest component of Teradyne’s revenue, increasing 90% year over year in 2025, a shift from its previous reliance on mobile applications. This transition reflects the company's strategic pivot to capitalize on AI-driven demand in high-performance computing.

Teradyne expects robust growth in the semiconductor test market, particularly in the compute segment, which is projected to expand significantly due to the rapid build-out of AI data centers and growth of edge AI. The company anticipates that the compute segment will drive a substantial portion of its revenue in 2026, with AI applications accounting for up to 70% of its revenue in the first quarter of 2026.

Teradyne Suffers From Stiff Competition

Teradyne is facing stiff competition from companies such as Advantest Corporation ATEYY and Cohu COHU. Both Advantest and Cohu are expanding their footprint in the semiconductor test market.

Advantest is expanding its footprint in the semiconductor test market by focusing on the growing demand for AI-related high-performance semiconductors, such as high-performance computing devices and high-performance DRAM for data centers.

Cohu’s expanding portfolio has been noteworthy. In September 2025, Cohu announced that a major U.S. semiconductor manufacturer and foundry services company chose its Eclipse platform for production testing of next-generation processors. 

The Eclipse systems feature Cohu’s T-Core Active Thermal Control, which offers precise thermal management up to 3kW dissipation with fast ramp rates. This improves yield and test repeatability. This scalable platform supports a variety of high-performance devices while lowering the total cost of ownership for IDMs, foundries and OSATs.

TER’s Share Price Performance, Valuation, and Estimates

Teradyne shares have surged 184.6% in the trailing six-month period, outperforming the Zacks Computer & Technology sector’s rise of 9.7% and the Zacks Electronics - Miscellaneous Products increase of 34.4%.

TER Stock's Performance

TER Benefits From Robust Semiconductor Test Segment: What's Ahead? image 0

Image Source: Zacks Investment Research

TER stock is trading at a premium with a forward 12-month Price/Sales of 11.77X compared with the Electronics - Miscellaneous Products industry’s 8.33X. TER has a Value Score of F.

TER's Valuation

TER Benefits From Robust Semiconductor Test Segment: What's Ahead? image 1

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for 2026 earnings is pegged at $5.91 per share, which has increased 16.11% the past 30 days. This suggests 49.24% year-over-year growth.

Teradyne, Inc. Price and Consensus

TER Benefits From Robust Semiconductor Test Segment: What's Ahead? image 2

Teradyne, Inc. price-consensus-chart | Teradyne, Inc. Quote

Teradyne currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23